Results 51 to 60 of about 11,659 (170)
Cardiovascular Safety of Anti-Sclerostin Therapy in Chronic Kidney Disease
, 2021 The significance of sclerostin for bone and cardiovascular health in patients with chronic kidney disease (CKD) is complex and incompletely understood. Experimental evidence suggests that anti-sclerostin therapy shows diminished efficacy on bone in the ...
Daniel Cejka
core +1 more source
Clinical Insights Into Hypercalcemia of Malignancy in Childhood
Pediatric Blood &Cancer, Volume 73, Issue 7, July 2026.ABSTRACT Hypercalcemia of malignancy (HCM) is a rare but life‐threatening metabolic emergency in children that occurs in less than 1% of pediatric cancer cases, with a reported incidence ranging from 0.4% to 1.0% across different studies. While it is observed in 10%–20% of adult malignancies, pediatric HCM remains relatively uncommon.
Hüseyin Anıl Korkmaz
wiley +1 more source
Macrophagic Sclerostin Loop2-ApoER2 Interaction Required by Sclerostin for Cardiovascular Protective Action. [PDF]
Adv Sci (Weinh)Abstract Therapeutic antibody against sclerostin loop2 promoted bone formation in postmenopausal osteoporosis but caused severe cardiovascular events in clinical applications. The studies of atherosclerosis and aortic aneurysm in SOST ki
Wang L +27 more
europepmc +3 more sources
Protein and Peptide Inhibitors of Mineralization: A Systematic Review of In Vitro Studies
Journal of Peptide Science, Volume 32, Issue 7, July 2026.In vitro evidence from crystallization assays demonstrates that peptides inhibit mineral nucleation and crystal growth through sequence‐dependent interactions (acidic residues and phosphorylation) with mineral surfaces. In cell cultures, these molecules reduce calcium deposition and ALP activity and modulate the expression of biomineralization‐related ...
Alberto Mimila‐Cortes +7 more
wiley +1 more source
Molecular Basis and Clinical Spectrum of WNT10A‐Related Oligodontia
Clinical Genetics, Volume 110, Issue 1, Page 3-14, July 2026.Cellular Mechanism behind WNT10A phenotypes. ABSTRACT WNT10A mutations, a major genetic determinant of dental agenesis and ectodermal dysplasia, exert profound effects on craniofacial development. Although classified as rare disorders, these mutations account for more than half of oligodontia cases, reflecting their critical role.
Perennes Elise +5 more
wiley +1 more source
Sclerostin and chronic kidney disease
, 2017 Chronic kidney disease (CKD) leads to the development of mineral and skeletal disturbances. They increase the risk of fractures, cardiovascular complications and, in consequence, decrease patients’ lifespan.
Beata Naumnik +3 more
core +1 more source
Sclerostin and DKK1 levels during 14 and 21 days of bed rest in healthy young men
, 2013 Objectives: Wnt signaling pathway may be crucial in the pathogenesis of disuse-induced bone loss. Sclerostin and DKK1, antagonists of the Wnt signaling pathway, were assessed during immobilization by bed rest in young, healthy people.
Heer, M. +4 more
core
Internalization of Sclerostin-GFP.
, 2013 (A) 293 cells stably over-expressing LRP6 (293-LRP6) or containing an empty pcDNA3 vector, were incubated with GFP or Sclerostin-GFP for 1.5 hours at 4°C.
Puck B. van Kasteren (408008) +10 more
core +1 more source
Sclerostin Enhances Adipocyte Differentiation in 3T3-L1 Cells [PDF]
, 2016 Sclerostin, a secreted protein encoded by the Sost gene, is produced by osteocytes and is inhibited by osteoblast differentiation and bone formation. Recently, a functional association between bone and fat tissue has been suggested, and a correlation ...
Taihiko Yamaguchi +7 more
core +1 more source
Health Science Reports, Volume 9, Issue 6, June 2026.ABSTRACT Background and Aims Osteosarcopenia, defined as the coexistence of osteoporosis and sarcopenia, is an emerging geriatric syndrome linked to the musculoskeletal decline associated with aging. It is correlated with an increased risk of falls, fractures, disability, and mortality.
Javeria Taj +6 more
wiley +1 more source